RWE strategies for targeted oncology therapies
Dear Kenneth,
Precision oncology is advancing rapidly, but generating the real-world evidence needed to support targeted therapies can be complex. Novel biomarkers may not be routinely tested, testing practices can vary across markets and sites, and low-prevalence patient populations can make studies harder to execute.
In this white paper, IQVIA explores how a more connected evidence approach can help address these challenges.
Learn how IQVIA’s approach can help support:
- Access to linked biomarker and clinical EMR data
- More efficient site selection and study feasibility assessment
- Retrospective testing of archival tissue samples
- RWE programs for novel and under-tested biomarkers
- 9AI-enabled precision oncology through imaging and pathology data
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).
© 2026 Marketing Masters Hub. All rights reserved.